Christine Katlama médecin française
Katlama, Christine
VIAF ID: 51773226 (Personal)
Permalink: http://viaf.org/viaf/51773226
Preferred Forms
- 100 0 _ ‡a Christine Katlama ‡c médecin française
- 200 _ | ‡a Katlama ‡b Christine
- 100 1 _ ‡a Katlama, Christine
-
-
- 100 1 _ ‡a Katlama, Christine
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
EVALUATION DE L'ATOVAQUONE DANS LE TRAITEMENT DE LA TOXOPLASMOSE CEREBRALE AU COURS DU SIDA : UNE ETUDE PILOTE CHEZ 23 PATIENTS | |
Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients | |
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients | |
Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir | |
Focus sur la lipodystrophie | |
Foscarnet and crystals in glomerular capillary lumens | |
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes | |
Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali | |
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. | |
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials | |
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) | |
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. | |
Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals | |
High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors | |
High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. | |
High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance | |
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial | |
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response | |
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies | |
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia | |
HIV | |
HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. | |
HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs | |
HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. | |
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. | |
HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects | |
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART | |
[HIV and cancer : What's new in 2017?] | |
HIV-related non-Hodgkin's lymphoma among European AIDS patients. AIDS in Europe Study Group. AIDS in Europe Study Group | |
Human CMV infection of the CNS: concordance between PCR detection in CSF and pathological examination. | |
Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and nondemented patients with acquired immunodeficiency syndrome | |
Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. | |
Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection | |
Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score | |
Impact of different antiretroviral therapy (ART) regimens on the evolution of soluble markers of inflammation and immune activation in HIV-infected patients. | |
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes | |
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease | |
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study | |
Impact of lean mass and bone density on glomerular filtration rate estimation in people living with HIV/AIDS. | |
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial | |
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. | |
An in vivo pharmacokinetic/pharmacodynamic model for antiretroviral combination | |
Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial | |
Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial). | |
Individualized antiretroviral therapeutic approaches: less can be more | |
Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. | |
Infection VIH/SIDA : mémento diagnostique | |
Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients. | |
Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis | |
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies | |
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial | |
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels | |
Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial | |
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial | |
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death | |
Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy? | |
Isolation of a new human retrovirus from West African patients with AIDS. | |
Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country | |
[LAV type II: a second retrovirus associated with AIDS in West Africa] | |
Legionellosis in HIV-1 infected patients. 4 case reports | |
Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis | |
L'infection à cytomégalovirus au cours du sida | |
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy | |
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group | |
Les nouvelles molécules anti-VIH : la place du raltégravir | |
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. | |
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients | |
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report | |
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. | |
SIDA | |
A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection | |
A Step Ahead on the HIV Collaboratory | |
VIH | |
VIH : complications et comorbidités | |
VIH : édition 2004 | |
VIH et sida : prise en charge et suivi du patient | |
VIH, hépatites virales, santé sexuelle | |
LA ZIDOVUDINE DANS LE TRAITEMENT DE L'INFECTION PAR LE VIRUS DE L'IMMUNODEFICIENCE HUMAINE |